MCM
MDCX

Marathon Capital Management’s Medicus Pharma MDCX Stock Holding History

Marathon Capital Management’s Portfolio MDCX Stock Details MDCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.12K Buy
+15,500
New +$16.2K ﹤0.01% 170

Other funds holding MDCX

ICP
Interchange Capital Partners Pittsburgh, Pennsylvania $317M AUM 12.76% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
MHC
May Hill Capital Cohasset, Massachusetts $398M AUM 23.9% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Marathon Capital Management's MDCX Position: Q1 2026 in Review

Marathon Capital Management opened a new position in Medicus Pharma (MDCX) in Q1 2026: 15,500 shares worth $7.12K. The stake represents ﹤0.01% of the portfolio and ranks #170 among its holdings.

21 funds tracked by Wall St. Rank hold MDCX as of Q1 2026.

  • Marathon Capital Management held 15,500 shares of Medicus Pharma worth $7.12K as of Q1 2026.
  • Medicus Pharma was a new Marathon Capital Management position in Q1 2026.
  • Medicus Pharma made up ﹤0.01% of Marathon Capital Management's portfolio in Q1 2026, its #170 holding.
  • 21 funds tracked by Wall St. Rank held Medicus Pharma as of Q1 2026.

Based on Marathon Capital Management's 13F filing for Q1 2026, filed 14 May 2026.